CURIDIUM PARTICIPERA AU 6EME RENDEZ-VOUS ANNUEL " ANNUAL EVOLUTION SUMMIT 2007 "

Curidium Medica plc ("Curidium" ou la "Société")


Londres, Royaume-Uni, le 15 octobre 2007, Curidium Medica plc, (LSE: CUR) société spécialisée dans la médecine personnalisée dont le but est d'apporter le bon médicament au bon patient, annonce qu'elle participera au 6ème rendez-vous annuel " Annual Evolution Summit 2007 " à Monte-Carlo, Monaco.

Dr. Anne Bruinvels, Founder & Chief Scientific Officer, will be presenting Curidium's recent progress in identifying targeted medicines and companion diagnostics to treat patients more effectively.

The presentation, entitled "The Way to Personalized Medicine: Identifying a Blood Diagnostic Test for Schizophrenia/Bipolar Disorder Patient Subgroups", is scheduled at 18.30 hours local time on 18th October 2007 at the Le Meridien Beach Plaza Hotel.

Ends

For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397

Chairman, Curidium Medica plc

Anne T. Bruinvels, PhD, +44 (0) 20 7554 8790

Founder & Chief Scientific Officer, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793

Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400

Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113

Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDxTM, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDxTM may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix(R), Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.

2. Improved therapies identified through novel drug targets.

3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc (c) 2002-2007. All rights reserved.

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.

Email: [email protected] Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791

This information is provided by RNS

The company news service from the London Stock Exchange



Copyright Hugin